GlucoTrack, Inc. (GCTK) is down by 24.56 percent during Tuesday trading despite announcing the successful completion of a ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GCTK) (“Glucotrack” or the “Company” ...

The Princess of Wales made just two public appearances in 2024 before declaring she was focusing on staying 'cancer-free'.